Furthermore, a translational window of opportunity study (DICER: denosumab in cervical cancer) starting in January 2019 is proposed investigating the effects of RANKL inhibition on the immune environment in patients with squamous carcinoma of the cervix. This evidence concerns the gene TNFSF11 and cervical cancer.